Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.

@article{Feng2010SuppressionOR,
  title={Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.},
  author={Shu Zhen Feng and Irina U Agoulnik and Anne Truong and Zhen Li and Chad J Creighton and Elena M. Kaftanovskaya and Rhea Pereira and Hee Dong Han and Gabriel L{\'o}pez-Berestein and Thomas Klonisch and Michael Ittmann and Anil Sood and Alexander I. Agoulnik},
  journal={Endocrine-related cancer},
  year={2010},
  volume={17 4},
  pages={1021-33}
}
Relaxin (RLN) is a small peptide hormone expressed in several cancers of reproductive and endocrine organs. Increased expression of RLN in prostate cancer correlates with aggressive cancer. RLN G-protein-coupled receptor (RLN family peptide receptor 1, RXFP1) is expressed in both androgen receptor (AR)-positive and -negative prostate cancers as well as in prostate cancer cell lines. RLN behaves as a cell growth factor and increases invasiveness and proliferation of cancer cells in vitro and in… CONTINUE READING